MedTrace Logo

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 755

Last updated 2015-02-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

LY2189265

Administered as a subcutaneous injection once weekly for 26 weeks

DRUG

Placebo

Administered as a subcutaneous injection once weekly for 26 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-09-30
Completion
2012-01-31

Countries

  • United States
  • Argentina
  • Brazil
  • Canada
  • Czechia
  • Denmark
  • India
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01149421 on ClinicalTrials.gov